CURx Pharmaceuticals Announces License Agreement with Gilead Sciences

SAN DIEGO, Feb. 19, 2014 -- (Healthcare Sales & Marketing Network) -- CURx Pharmaceuticals today announced it has entered into a global license agreement with Gilead Sciences, Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pse... Biopharmaceuticals, Drug Delivery, LicensingCURx Pharmaceuticals, Gilead Sciences, Fosfomycin, Tobramycin, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news